Monitor for near-term financing activity — the planned Phase 3 trial and 2026 catalysts are contingent on funding. Positive clinical data supports upside potential, but financial runway is tight and dilution risk is high. Watch for Q1 2026 cash burn and any partnerships or offerings.
Price Chart
Executive Summary
CervoMed reported full-year 2025 financial results and corporate updates, highlighting positive Phase 2b data for its lead drug neflamapimod in dementia with Lewy bodies (DLB), regulatory alignment for a Phase 3 trial, and a robust 2026 catalyst pipeline. However, the company's cash position declined to $20.9M from $38.9M year prior, with grant revenue halved and net loss nearly doubled, raising funding concerns ahead of planned Phase 3 initiation.
Key Financial Metrics
Key Facts
- Positive Phase 2b RewinD-LB data presented at CTAD 2025 showing clinical benefit in DLB patients, particularly those without Alzheimer's co-pathology
- FDA and global regulator alignment secured for Phase 3 trial design in DLB; trial planned for H2 2026 pending funding
- Cash position dropped from $38.9M (2024) to $20.9M (2025), with only ~6 months of runway as of March 2026
- Grant revenue fell to $4.0M in 2025 from $9.7M in 2024 due to completion of RewinD-LB trial phases
- R&D expenses rose to $21.8M (2025) from $18.8M (2024) due to manufacturing improvements and new trials
- Net loss widened to $27.0M in 2025 from $16.2M in 2024
- Multiple 2026 catalysts expected: Phase 3 DLB trial start, topline data from RAS and nfvPPA trials, and initiation of EXPERTS-ALS trial
Financial Impact
Revenue down 58.8% YoY (grant-based), R&D up 15.9%, net loss up 66.7%; cash runway ~6 months as of March 2026
Risk Factors
- Insufficient cash to fund Phase 3 trial without dilutive financing or partnership
- Clinical trial delays if funding is not secured
- Dependence on grant revenue, which is non-recurring and volatile
- Regulatory or clinical setbacks despite positive Phase 2b data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.25 (0.00%) |
Oct 13, 2026 13d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.25 (−0.88%) |
Oct 9, 2026 16d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.25 (−10.36%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.25 (−9.27%) |
Aug 10, 2026 10w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.25 (−27.18%) |
Aug 4, 2026 11w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.25 (−19.64%) |
Aug 4, 2026 11w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.25 (−19.64%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.25 (+32.02%) |
Jul 6, 2026 15w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.25 (+34.21%) |
Jun 22, 2026 17w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.25 (+39.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers